Atara Biotherapeutics (ATRA) Expected to Announce Earnings on Friday

Atara Biotherapeutics (NASDAQ:ATRA) is expected to be releasing its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect Atara Biotherapeutics to post earnings of ($0.68) per share and revenue of $0.70 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 10:30 AM ET.

Atara Biotherapeutics Price Performance

Shares of ATRA stock opened at $5.42 on Wednesday. The company has a market cap of $39.08 million, a PE ratio of 2.49 and a beta of -0.44. Atara Biotherapeutics has a 1 year low of $3.92 and a 1 year high of $19.15. The stock’s 50 day simple moving average is $7.99 and its two-hundred day simple moving average is $11.82.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Atara Biotherapeutics in a report on Monday, December 29th. New Street Research set a $6.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, January 13th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $6.00 target price (down from $25.00) on shares of Atara Biotherapeutics in a research report on Tuesday, January 13th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $6.00.

Insider Transactions at Atara Biotherapeutics

In other news, major shareholder Innovation Ltd Panacea sold 80,554 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $6.07, for a total transaction of $488,962.78. Following the transaction, the insider directly owned 1,324,446 shares of the company’s stock, valued at approximately $8,039,387.22. This trade represents a 5.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Atara Biotherapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 1,457 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $327,000. Raymond James Financial Inc. bought a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $31,000. Vanguard Group Inc. lifted its stake in Atara Biotherapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock worth $2,915,000 after acquiring an additional 12,677 shares during the period. Finally, Mackenzie Financial Corp grew its holdings in Atara Biotherapeutics by 183.5% during the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after acquiring an additional 41,302 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.